BACKGROUND: High levels of glycoprotein (GP) IIb/IIIa receptor inhibition are required to prevent arterial thrombosis following percutaneous coronary intervention. Ex-vivo turbidometric platelet aggregation in citrate anticoagulated blood samples has been the primary method previously utilized to derive dose regimens for administering platelet GP IIb/IIIa inhibitors. Enhanced GP IIb/IIIa binding and inhibition of platelet aggregation for eptifibatide secondary to citrate induced reduction of ionized plasma calcium concentrations has been reported. METHODS/ RESULTS: We evaluated the differential effects of citrate versus PPACK anticoagulation on turbidometric platelet inhibition in normal volunteers by eptifibatide, tirofiban or abciximab. The decrease in ionized calcium afforded by citrate was associated with enhanced in vitro platelet inhibition for all three GP IIb/IIIa inhibitors, including abciximab. The magnitude of citrate effect was greatest for eptifibatide. Both tirofiban and abciximab have similar citrate calcium chelation associated enhancement of measured platelet inhibition. CONCLUSION: Accurate assessment and comparison of platelet inhibition by GP IIb/IIIa inhibitors may require avoidance of calcium chelating anticoagulants.
BACKGROUND: High levels of glycoprotein (GP) IIb/IIIa receptor inhibition are required to prevent arterial thrombosis following percutaneous coronary intervention. Ex-vivo turbidometric platelet aggregation in citrate anticoagulated blood samples has been the primary method previously utilized to derive dose regimens for administering platelet GP IIb/IIIa inhibitors. Enhanced GP IIb/IIIa binding and inhibition of platelet aggregation for eptifibatide secondary to citrate induced reduction of ionized plasma calcium concentrations has been reported. METHODS/ RESULTS: We evaluated the differential effects of citrate versus PPACK anticoagulation on turbidometric platelet inhibition in normal volunteers by eptifibatide, tirofiban or abciximab. The decrease in ionizedcalcium afforded by citrate was associated with enhanced in vitro platelet inhibition for all three GP IIb/IIIa inhibitors, including abciximab. The magnitude of citrate effect was greatest for eptifibatide. Both tirofiban and abciximab have similar citrate calcium chelation associated enhancement of measured platelet inhibition. CONCLUSION: Accurate assessment and comparison of platelet inhibition by GP IIb/IIIa inhibitors may require avoidance of calcium chelating anticoagulants.
Authors: D J Kereiakes; T M Broderick; E M Roth; D Whang; T Shimshak; J P Runyon; C Hattemer; J Schneider; P Lacock; M Mueller; C W Abbottsmith Journal: Am J Cardiol Date: 1999-08-15 Impact factor: 2.778
Authors: D J Kereiakes; T M Broderick; E M Roth; D Whang; M Mueller; P Lacock; L C Anderson; W Howard; C Blanck; J Schneider; C A Abbottsmith Journal: J Thromb Thrombolysis Date: 2000-02 Impact factor: 2.300
Authors: J C O'shea; M Madan; W J Cantor; C M Pacchiana; S Greenberg; D M Joseph; M M Kitt; T J Lorenz; J E Tcheng Journal: Am Heart J Date: 2000-12 Impact factor: 4.749
Authors: Melanie M White; Rajini Krishnan; Teddi J Kueter; Mary V Jacoski; Lisa K Jennings Journal: J Thromb Thrombolysis Date: 2004-12 Impact factor: 2.300
Authors: Jihong Li; Spandana Vootukuri; Yi Shang; Ana Negri; Jian-Kang Jiang; Mark Nedelman; Thomas G Diacovo; Marta Filizola; Craig J Thomas; Barry S Coller Journal: Arterioscler Thromb Vasc Biol Date: 2014-08-21 Impact factor: 8.311